Company Overview and News

4
TMUS / T-Mobile US, Inc. AMENDMENT NO. 2 TO FORM S-4

2018-10-19 sec.gov - 1
Amendment No. 2 to Form S-4 Table of Contents As filed with the Securities and Exchange Commission on October 19, 2018 Registration No. 333-226435
TMUS

39
T-Mobile Investors Face An Impossible Decision

2018-10-19 seekingalpha
The "New T-Mobile" is on pause and investors are waiting with little in the way of answers.
S TMUS VZ

42
Turnaround Dividend Stock With A 10% Yield, Big Growth, Higher Guidance And No K-1

2018-10-19 seekingalpha - 2
Revenue grew 44%, free cash flow rose 820%, and net income rose 320% in Q2 '18. Management increased guidance for the rest of 2018.
GIS S TMUS CTL APR APRLY

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-10-18 sec.gov
425 Desktop The following digital advertisements were made available by T-Mobile US, Inc. in connection with the transaction: Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Sprint Corporation Commission File No.: 001-04721
TMUS

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-10-18 sec.gov
425 Desktop The following digital advertisements were made available by T-Mobile US, Inc. in connection with the transaction: Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Sprint Corporation Commission File No.: 001-04721
TMUS

65
Asia's technology bear isn't ready to hibernate

2018-10-17 businesstimes.com.sg - 1
Until recently, US technology companies seemed immune to the escalating trade war with China. Their Asian peers, meanwhile, have collapsed.
FB TMUSP TMUS NFLX GOOG SFTBF WFM BABA S GOOGL 0700 AAPL 9984 BIDU SFTBY

38
Sprint sells mobile advertising unit to InMobi

2018-10-17 channelnewsasia
Sprint Corp has sold the mobile data and advertising company it created in 2012 to InMobi, which provides technology for marketers, in an all-stock deal, the companies said on Wednesday.
S TMUSP TMUS TWX TWC

5
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-10-15 sec.gov - 2
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-10-15 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

38
Ericsson (ERIC) to Report Q3 Earnings: What Lies Ahead?

2018-10-15 zacks
Ericsson (ERIC - Free Report) is scheduled to report third-quarter 2018 results before the opening bell on Oct 18. The company has a bleak earnings history with three colossal earnings misses in the trailing four quarters, with an average negative surprise of 291.7%. Let's see how things are shaping up for this announcement. Factors to Consider The information and communications technology solutions provider has been grappling with shrinking markets and stiff competition from other established players in the market.
SCMWY S TMUSP TMUS GJH SWZCF UZA CTL USM UZC UZB

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-10-11 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-10-11 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

8
Qorvo Could Have Reached An Inflection Point

2018-10-10 seekingalpha
While the execution risk remains, the risk profile appears favorable due to strong IoT/5G secular tailwinds.
SOXX SWKS QRVO SSNLF T TMUS ADI AAPL VZ

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-10-10 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

3
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-10-10 sec.gov
425 Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
TMUS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 872590203